Ainsworth Sean 4
4 · Ocuphire Pharma, Inc. · Filed Oct 20, 2022
Insider Transaction Report
Form 4
Ainsworth Sean
Director
Transactions
- Exercise of In-Money
Common Stock
2022-10-19$0.00/sh+1,574$0→ 41,239 total - Exercise of In-Money
Series B Warrant (right to buy)
2022-10-19−1,574→ 0 totalExercise: $0.00From: 2020-11-19Exp: 2022-10-20→ Common Stock (1,574 underlying)
Footnotes (1)
- [F1]The expiration date of the Series B Warrants occurred on the later of (x) the Reservation Date (as defined in the Series B Warrants) and (y) the date on which the Series B Warrants were exercised in full.